The Management Strategies of Interventional Therapy and Drug Therapy of Complicated Pancreatic Neuroendocrine Neoplasms with Liver Metastases
-
摘要: 胰腺神经内分泌肿瘤(pancreatic neuroendocrine neoplasm, pNEN)初诊时已有60%以上患者出现远处转移, 最常见转移部位是肝脏, 其中65.5%肝转移无法手术切除, 严重影响预后。pNEN复杂肝转移的治疗基础是全身用药, 包括生长抑素类似物、靶向药物及化疗, 可抗激素分泌和抗增殖, 但其总体客观反应率(objective response ratio, ORR)并不高。经肝动脉途径介入治疗可安全、快速降低肝肿瘤负荷和激素分泌, 显著提高ORR, 其治疗方式包括肝动脉栓塞术(trans-arterial embolization, TAE)、肝动脉灌注化疗栓塞术(trans-arterial chemoembolization, TACE)和放射性微球栓塞术, 三者在疗效上并无显著差异。但TAE的ORR相对较高, 且无TACE的化疗副作用, 应用较广泛。多肽-受体介导的放射性核素治疗对高表达生长抑素受体、肝转移瘤负荷小的低级别肿瘤疗效颇佳, 但亦需注意其骨髓抑制及放射性肾损伤等并发症。pNEN复杂肝转移需采取多种手段综合治疗, 总体策略为先尽可能通过药物和介入治疗减小肝转移瘤负荷, 创造条件行胰腺原发病灶切除术。Abstract: Pancreatic neuroendocrine neoplasms (pNENs) are the most common type of gastro-entero-pancreatic neuroendocrine tumor. Over 60% of patients were detected with distant metastases after the initial diagnosis. Liver is the most common metastatic site, 65.5% of liver metastases are unresectable. The basic treatment strategy is system therapy, mainly including somatostatin analogues, target therapy, and chemotherapy with the effect of anti-hormone secretion and anti-proliferation. But the objective response ratio (ORR) of system therapy is mild. Hepatic artery direct therapies, including trans-arterial embolization (TAE), trans-arterial chemoembolization (TACE), and trans-arterial radioembolization (TARE) can reduce the hepatic tumor burden fast and safely. The ORR can be improved too. There is no significant difference in the efficacy of the three methods. TAE has the highest ORR among the three methods but no side effect of chemotherapy of TACE, so that it is widely used in clinical practice. The outcome of peptide receptor radionuclide therapy (PRRT) was proved to be satisfactory in the low-grade or intermediate grade pNENs that expressed high levels of somatostatin receptor or had a moderately metastatic hepatic tumor burden. The severe complications from PRRT are myelo-suppression and radiation nephrotoxicity. The combined therapy should be applied to the treatment of complicated pNENs with liver metastases. The general strategies are reducing the hepatic tumor burden as soon as possible by firstly applying system drugs and interventional therapy, and then the primary tumor should be resected in elective surgery.
-
Key words:
- neuroendocrine neoplasm /
- pancreas /
- liver metastases /
- interventional therapy /
- system therapy
利益冲突 无 -
[1] Dasari A, Shen C, Halperin D, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States[J]. JAMA Oncol, 2017, 3:1335-1342. doi: 10.1001/jamaoncol.2017.0589 [2] 陈野野, 刘洪生, 李单青, 等.胸腺神经内分泌肿瘤手术治疗及预后因素[J].协和医学杂志, 2016, 7:190-194. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201603006 [3] 陈野野, 刘洪生, 李单青.肺大细胞神经内分泌癌的诊断及治疗[J].协和医学杂志, 2019, 10:393-397. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201904019 [4] 张艺璇, 陈洁.抗血管生成靶向药物在胰腺神经内分泌肿瘤治疗中的应用及研究进展[J].中国普通外科杂志, 2019, 28:1042-1047. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgptwkzz201909002 [5] Strosberg J, Cheema A, Kvols L. A Review of Systemic and Liver-Directed Therapies for Metastatic Neuroendocrine Tumors of the Gastroenteropancreatic Tract[J]. Cancer Control, 2011, 18:127-137. doi: 10.1177/107327481101800207 [6] Fan J, Zhang Y, Shi S, et al. A nation-wide retrospective epidemiological study of gastroenteropancreatic neuroendocr-ine neoplasms in china[J]. Oncotarget, 2017, 8:71699-71708. doi: 10.18632/oncotarget.17599 [7] Halfdanarson TR, Rabe KG, Rubin J, et al. Pancreatic neuroendocrine tumors (PNETs):incidence, prognosis and recent trend toward improved survival[J]. Ann Oncol, 2008, 19:1727-1733. doi: 10.1093/annonc/mdn351 [8] Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary[J]. Neuroendocrinology, 2012, 95:157-176. doi: 10.1159/000335597 [9] Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors[J]. World J Gastroenterol, 2010, 16:2963-2970. doi: 10.3748/wjg.v16.i24.2963 [10] Pavel M, O'Toole D, Costa F, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site[J]. Neuroendocrinology, 2016, 103:172-185. doi: 10.1159/000443167 [11] Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364:514-523. doi: 10.1056/NEJMoa1009290 [12] de Mestier L, Walter T, Brixi H, et al. Comparison of Temozolomide-Capecitabine to 5-Fluorouracile-Dacarbazine in 247 Patients with Advanced Digestive Neuroendocrine Tumors Using Propensity Score Analyses[J]. Neuroendocrinology, 2019, 108:343-353. doi: 10.1159/000498887 [13] Moertel C, Kvols L, O'Connell M, et al. Treatment of Neuroendocrine Carcinomas With Combined Etoposide and Cisplatin. Evidence of Major Therapeutic Activity in the Anaplastic Variants of These Neoplasms[J]. Cancer, 1991, 68:227-232. doi: 10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I [14] Elias D, Lefevre JH, Duvillard P, et al. Hepatic metastases from neuroendocrine tumors with a "thin slice" pathological examination:they are many more than you think[J]. Ann Surg, 2010, 251:307-310. doi: 10.1097/SLA.0b013e3181bdf8cf [15] Ronot M, Cuccioli F, Dioguardi Burgio M, et al. Neuroendocrine liver metastases:Vascular patterns on triple-phase MDCT are indicative of primary tumour location[J]. Eur J Radiol, 2017, 89:156-162. doi: 10.1016/j.ejrad.2017.02.007 [16] Pericleous M, Caplin ME, Tsochatzis E, et al. Hepatic artery embolization in advanced neuroendocrine tumors:Efficacy and long-term outcomes[J]. Asia Pac J Clin Oncol, 2016, 12:61-69. doi: 10.1111/ajco.12438 [17] 刘一铭, 连帆, 周翔飞, 等.肝动脉栓塞术联合长效奥曲肽降低低级别神经内分泌瘤肝转移负荷的疗效及安全性分析[J].中华医学杂志, 2019, 99:1142-1146. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhyx201915005 [18] Frilling A, Clift AK. Therapeutic strategies for neuroendocr-ine liver metastases[J]. Cancer, 2015, 121:1172-1186. doi: 10.1002/cncr.28760 [19] Yang TX, Chua TC, Morris DL. Radioembolization and chemoembolization for unresectable neuroendocrine liver metastases- a systematic review[J]. Surg Oncol, 2012, 21:299-308. doi: 10.1016/j.suronc.2012.07.001 [20] Fiore F, Del Prete M, Franco R, et al. Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors[J]. Endocrine, 2014, 47:177-182. doi: 10.1007/s12020-013-0130-9 [21] Saxena A, Chua TC, Bester L, et al. Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases:a critical appraisal of 48 cases[J]. Ann Surg, 2010, 251:910-916. doi: 10.1097/SLA.0b013e3181d3d24a [22] Engelman ES, Leon-Ferre R, Naraev BG, et al. Comparison of transarterial liver-directed therapies for low-grade metastatic neuroendocrine tumors in a single institution[J]. Pancreas, 2014, 43:219-225. doi: 10.1097/MPA.0000000000000030 [23] Zener R, Yoon H, Ziv E, et al. Outcomes After Transarterial Embolization of Neuroendocrine Tumor Liver Metastases Using Spherical Particles of Different Sizes[J]. Cardiovasc Intervent Radiol, 2019, 42:569-576. doi: 10.1007/s00270-018-02160-y [24] Makary MS, Kapke J, Yildiz V, et al. Conventional versus Drug-Eluting Bead Transarterial Chemoembolization for Neuroendocrine Tumor Liver Metastases[J]. J Vasc Interv Radiol, 2016, 27:1298-1304. doi: 10.1016/j.jvir.2016.05.014 [25] Bhagat N, Reyes DK, Lin M, et al. Phase Ⅱ study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases:high incidence of biliary injury[J]. Cardiovasc Intervent Radiol, 2013, 36:449-459. doi: 10.1007/s00270-012-0424-y [26] Goering J, Mahvi D, Niederhuber J, et al. Cryoablation and Liver Resection for Noncolorectal Liver Metastases[J]. Am J Surg, 2002, 183:384-389. doi: 10.1016/S0002-9610(02)00806-1 [27] Kose E, Kahramangil B, Aydin H, et al. Outcomes of laparoscopic tumor ablation for neuroendocrine liver metastases:a 20-year experience[J]. Surg Endosc, 2020, 34:249-256. doi: 10.1007/s00464-019-06759-1 [28] Farley HA, Pommier RF. Treatment of Neuroendocrine Liver Metastases[J]. Surg Oncol Clin N Am, 2016, 25:217-225. doi: 10.1016/j.soc.2015.08.010 [29] Weckbecker G, Lewis I, Albert R, et al. Opportunities in somatostatin research:biological, chemical and therapeutic aspects[J]. Nat Rev Drug Discov, 2003, 2:999-1017. doi: 10.1038/nrd1255 [30] Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors:a report from the PROMID Study Group[J]. J Clin Oncol, 2009, 27:4656-4663. doi: 10.1200/JCO.2009.22.8510 [31] Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371:224-233. doi: 10.1056/NEJMoa1316158 [32] Kulke M, Mayer R. Carcinoid tumors[J]. N Engl J Med, 1999, 340:858-868. doi: 10.1056/NEJM199903183401107 [33] Terris B, Scoazec J, Rubbia L, et al. Expression of Vascular Endothelial Growth Factor in Digestive Neuroendocrine Tumours[J]. Histopathology, 1998, 32:133-138. doi: 10.1046/j.1365-2559.1998.00321.x [34] Faivre S, Niccoli P, Castellano D, et al. Sunitinib in pancreatic neuroendocrine tumors:updated progression-free survival and final overall survival from a phase Ⅲ randomized study[J]. Ann Oncol, 2017, 28:339-343. doi: 10.1093/annonc/mdw561 [35] Wang Y, Jin K, Tan H, et al. Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors:a multicenter retrospective study in China[J]. Cancer Chemother Pharmacol, 2017, 80:507-516. doi: 10.1007/s00280-017-3367-9 [36] Xu J, Li J, Bai C, et al. Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors:A Multicenter, Single-Arm, Open-Label, Phase Ib/Ⅱ Trial[J]. Clin Cancer Res, 2019, 25:3486-3494. [37] Yao JC, Pavel M, Lombard-Bohas C, et al. Everolimus for the Treatment of Advanced Pancreatic Neuroendocrine Tumors:Overall Survival and Circulating Biomarkers From the Randomized, Phase Ⅲ RADIANT-3 Study[J]. J Clin Oncol, 2016, 34:3906-3913. doi: 10.1200/JCO.2016.68.0702 [38] Ezziddin S, Khalaf F, Vanezi M, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advan-ced grade 1/2 pancreatic neuroendocrine tumours[J]. Eur J Nucl Med Mol Imaging, 2014, 41:925-933. doi: 10.1007/s00259-013-2677-3 [39] Claringbold PG, Turner JH. Pancreatic Neuroendocrine Tumor Control:Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy[J]. Neuroendocrinology, 2016, 103:432-439. doi: 10.1159/000434723 [40] Campana D, Capurso G, Partelli S, et al. Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours:factors associated with response and suggestions for therapeutic sequence[J]. Eur J Nucl Med Mol Imaging, 2013, 40:1197-1205. doi: 10.1007/s00259-013-2402-2
点击查看大图
计量
- 文章访问数: 409
- HTML全文浏览量: 51
- PDF下载量: 67
- 被引次数: 0